• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种设计用于提高稳定性的具有延长半衰期的“Fc沉默”IgG1形式。

An "Fc-Silenced" IgG1 Format With Extended Half-Life Designed for Improved Stability.

作者信息

Borrok M Jack, Mody Neil, Lu Xiaojun, Kuhn Megan L, Wu Herren, Dall'Acqua William F, Tsui Ping

机构信息

Department of Antibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, Maryland 20878.

Department of Formulation Sciences, MedImmune LLC, Gaithersburg, Maryland 20878.

出版信息

J Pharm Sci. 2017 Apr;106(4):1008-1017. doi: 10.1016/j.xphs.2016.12.023. Epub 2017 Jan 3.

DOI:10.1016/j.xphs.2016.12.023
PMID:28057542
Abstract

Multiple mutation combinations in the IgG Fc have been characterized to tailor immune effector function or IgG serum persistence to fit desired biological outcomes for monoclonal antibody therapeutics. An unintended consequence of introducing mutations in the Fc (particularly the C2 domain) can be a reduction in biophysical stability which can correlate with increased aggregation propensity, poor manufacturability, and lower solubility. Herein, we characterize the changes in IgG conformational and colloidal stability when 2 sets of C2 mutations "TM" (L234F/L235E/P331S) and "YTE" (M252Y/S254T/T256E) are combined to generate an antibody format lacking immune receptor binding and exhibiting extended half-life. In addition to significantly lowered thermostability, we observe greater conformational flexibility for TM-YTE in C2, increased self-association, and poorer solubility and aggregation profiles. To improve these properties, we dissected the contributions of individual mutations within TM-YTE on thermostability and substituted destabilizing mutations with new mutations that raise thermostability. One novel combination, FQQ-YTE (L234F/L235Q/K322Q/M252Y/S254T/T256E), had significantly improved conformational and colloidal stability, and was found to retain the same biological activities as TM-YTE (extended half-life and lack of antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activity). Our engineering approach offers a way to improve the developability of antibodies containing Fc mutations while retaining tailored biological activity.

摘要

IgG Fc中的多种突变组合已被表征,以调整免疫效应功能或IgG血清持久性,以适应单克隆抗体治疗所需的生物学结果。在Fc(特别是C2结构域)中引入突变的一个意外后果可能是生物物理稳定性降低,这可能与聚集倾向增加、可制造性差和溶解度降低相关。在此,我们表征了将两组C2突变“TM”(L234F/L235E/P331S)和“YTE”(M252Y/S254T/T256E)组合以产生缺乏免疫受体结合并具有延长半衰期的抗体形式时IgG构象和胶体稳定性的变化。除了显著降低的热稳定性外,我们还观察到TM-YTE在C2中的构象灵活性更高、自缔合增加以及溶解度和聚集谱更差。为了改善这些特性,我们剖析了TM-YTE中单个突变对热稳定性的贡献,并用提高热稳定性的新突变取代了不稳定突变。一种新的组合,FQQ-YTE(L234F/L235Q/K322Q/M252Y/S254T/T256E),具有显著改善的构象和胶体稳定性,并被发现保留了与TM-YTE相同的生物学活性(延长半衰期以及缺乏抗体依赖性细胞介导的细胞毒性和补体依赖性细胞毒性活性)。我们的工程方法提供了一种在保留定制生物学活性的同时提高含Fc突变抗体可开发性的方法。

相似文献

1
An "Fc-Silenced" IgG1 Format With Extended Half-Life Designed for Improved Stability.一种设计用于提高稳定性的具有延长半衰期的“Fc沉默”IgG1形式。
J Pharm Sci. 2017 Apr;106(4):1008-1017. doi: 10.1016/j.xphs.2016.12.023. Epub 2017 Jan 3.
2
Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.为延长血清半衰期而改造的突变型IgG1单克隆抗体的构象动力学变化与物理稳定性之间的相关性。
MAbs. 2015;7(1):84-95. doi: 10.4161/19420862.2014.985494.
3
An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.一种 IgG 的工程化 Fc 变体通过结构干扰消除了所有免疫效应功能。
Methods. 2014 Jan 1;65(1):114-26. doi: 10.1016/j.ymeth.2013.06.035. Epub 2013 Jul 17.
4
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies.Fc 工程化 SARS-CoV-2 中和抗体的可开发性分析。
MAbs. 2023 Jan-Dec;15(1):2152526. doi: 10.1080/19420862.2022.2152526.
5
Structural characterization of a human Fc fragment engineered for extended serum half-life.一种经过工程改造以延长血清半衰期的人Fc片段的结构表征。
Mol Immunol. 2009 May;46(8-9):1750-5. doi: 10.1016/j.molimm.2009.01.026. Epub 2009 Feb 27.
6
An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies.一种具有两个突变的 Fc 变体赋予 IgG 抗体延长的血清半衰期和增强的效应功能。
Exp Mol Med. 2022 Nov;54(11):1850-1861. doi: 10.1038/s12276-022-00870-5. Epub 2022 Nov 1.
7
Effect of the ADCC-Modulating Mutations and the Selection of Human IgG Isotypes on Physicochemical Properties of Fc.ADCC 调节突变和人 IgG 同种型选择对 Fc 的物理化学性质的影响。
J Pharm Sci. 2022 Sep;111(9):2411-2421. doi: 10.1016/j.xphs.2022.06.014. Epub 2022 Jun 26.
8
Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.通过赋予IgG与FcαRI(CD89)结合能力来增强抗体依赖性细胞介导的细胞毒性。
MAbs. 2015;7(4):743-51. doi: 10.1080/19420862.2015.1047570.
9
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).为增强与新生儿Fc受体(FcRn)的结合而改造的人IgG1的特性。
J Biol Chem. 2006 Aug 18;281(33):23514-24. doi: 10.1074/jbc.M604292200. Epub 2006 Jun 21.
10
Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability.构建具有优化可开发性且缺乏效应功能的IgG支架。
J Biol Chem. 2017 Feb 3;292(5):1865-1875. doi: 10.1074/jbc.M116.748525. Epub 2016 Dec 19.

引用本文的文献

1
Engineering FcRn binding kinetics dramatically extends antibody serum half-life and enhances therapeutic potential.工程化改造FcRn结合动力学可显著延长抗体血清半衰期并增强治疗潜力。
J Biol Eng. 2025 Apr 18;19(1):35. doi: 10.1186/s13036-025-00506-y.
2
Using IMGT unique numbering for IG allotypes and Fc-engineered variants of effector properties and half-life of therapeutic antibodies.使用IMGT对免疫球蛋白同种异型以及治疗性抗体效应特性和半衰期的Fc工程变体进行独特编号。
Immunol Rev. 2024 Nov;328(1):473-506. doi: 10.1111/imr.13399. Epub 2024 Oct 4.
3
FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models.
FZ-AD005,一种新型靶向 DLL3 的抗体药物偶联物,含有拓扑异构酶 I 抑制剂,在临床前模型中显示出强大的抗肿瘤活性。
Mol Cancer Ther. 2024 Oct 1;23(10):1367-1377. doi: 10.1158/1535-7163.MCT-23-0701.
4
Impact of structural modifications of IgG antibodies on effector functions.IgG 抗体结构修饰对效应功能的影响。
Front Immunol. 2024 Jan 8;14:1304365. doi: 10.3389/fimmu.2023.1304365. eCollection 2023.
5
Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response.抗体药物偶联物在乳腺癌中的应用:克服耐药性和增强免疫反应。
J Clin Invest. 2023 Sep 15;133(18):e172156. doi: 10.1172/JCI172156.
6
A Dual-Approach Strategy to Optimize the Safety and Efficacy of Anti-Zika Virus Monoclonal Antibody Therapeutics.一种优化抗寨卡病毒单克隆抗体治疗安全性和疗效的双途径策略。
Viruses. 2023 May 11;15(5):1156. doi: 10.3390/v15051156.
7
Plant-Produced Anti-Zika Virus Monoclonal Antibody Glycovariant Exhibits Abrogated Antibody-Dependent Enhancement of Infection.植物产生的抗寨卡病毒单克隆抗体糖变体表现出感染的抗体依赖性增强作用被消除。
Vaccines (Basel). 2023 Mar 29;11(4):755. doi: 10.3390/vaccines11040755.
8
Impact of IgG subclass on monoclonal antibody developability.IgG 亚类对单克隆抗体可开发性的影响。
MAbs. 2023 Jan-Dec;15(1):2191302. doi: 10.1080/19420862.2023.2191302.
9
Design of a chimeric ACE-2/Fc-silent fusion protein with ultrahigh affinity and neutralizing capacity for SARS-CoV-2 variants.一种对SARS-CoV-2变体具有超高亲和力和中和能力的嵌合ACE-2/Fc沉默融合蛋白的设计。
Antib Ther. 2023 Jan 20;6(1):59-74. doi: 10.1093/abt/tbad001. eCollection 2023 Jan.
10
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies.Fc 工程化 SARS-CoV-2 中和抗体的可开发性分析。
MAbs. 2023 Jan-Dec;15(1):2152526. doi: 10.1080/19420862.2022.2152526.